Erasca gets FDA Fast Track for ERAS-0015 in metastatic pancreatic cancer

Erasca, Inc.

FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma on Aug 24, 2026.
FTD may enable accelerated approval, priority review, and rolling review if criteria met.
Company plans phase 3 trial in pancreatic cancer and two registration-enabling trials in lung cancer.
FTD does not change approval standards; FDA may later revoke designation or not shorten review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.